Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
76 hedge funds and large institutions have $243M invested in Kezar Life Sciences in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 8 closing their positions.
9,990% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $10K
62% more capital invested
Capital invested by funds: $150M → $243M (+$92.7M)
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 75 → 76 (+1)
0.08% more ownership
Funds ownership: 5.75% → 5.83% (+0.08%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.9M |
| 2 |
O
OrbiMed
New York
|
+$3.92M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.72M |
| 4 |
Goldman Sachs
New York
|
+$1.04M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$894K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.22M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.79M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$2.61M |
| 4 |
Morgan Stanley
New York
|
-$2.41M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.08M |
KZR Hedge Fund Activity: Q3 2021 in Review
76 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2021, worth a combined $243M — up 62% from $150M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KZR positions and 8 closed out — a net gain of 1 holder — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Logos Global Management, adding an estimated $11.9M. The largest seller was Millennium Management, cutting an estimated $5.22M.
- 76 institutional investors held Kezar Life Sciences (KZR) as of Q3 2021, up from 75 in Q2 2021.
- Funds reported $243M of Kezar Life Sciences stock for Q3 2021, up 62% quarter-over-quarter.
- 9 funds opened new Kezar Life Sciences positions in Q3 2021 and 8 closed out, a net change of +1 holder.
- The largest Kezar Life Sciences buyer in Q3 2021 was Logos Global Management, an estimated $11.9M added.
- The largest Kezar Life Sciences seller in Q3 2021 was Millennium Management, an estimated $5.22M sold.
Based on aggregated 13F filings for Q3 2021.